Welcome to our dedicated page for Tg Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on Tg Therapeutics stock.
TG Therapeutics, Inc. (NASDAQ: TGTX) is a commercial-stage biopharmaceutical company focused on B-cell diseases, with news flow centered on its CD20-targeted monoclonal antibody BRIUMVI (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS). This news page aggregates company announcements, clinical data updates, financial results, and corporate presentations related to TGTX stock.
Recent press releases highlight preliminary and reported revenue from BRIUMVI, including disclosures that product revenue consists primarily of net product sales of BRIUMVI in the United States and sales to ex-U.S. partners. Investors can follow updates on revenue guidance, operating expense targets, and commentary on how BRIUMVI commercialization influences overall company performance.
TG Therapeutics also issues frequent news about its development programs. These items include progress in the ENHANCE Phase 3b trial evaluating a simplified intravenous dosing schedule for BRIUMVI, the Phase 3 pivotal program for subcutaneous ublituximab, and the Phase 1 trial of azer-cel, an allogeneic CD19 CAR T therapy in autoimmune disease. Additional releases cover long-term ULTIMATE I & II trial data, real-world ENABLE observational study outcomes, and schedules of data presentations at neurology and multiple sclerosis congresses.
Corporate news includes participation in major healthcare and biotechnology investor conferences, rankings such as the Deloitte Technology Fast 500, and announcements of share repurchase authorizations. By following this TGTX news feed, readers can monitor how clinical results, regulatory milestones, commercialization updates, and financial disclosures intersect for TG Therapeutics and its lead therapy BRIUMVI.
TG Therapeutics (NASDAQ: TGTX) reported fourth-quarter 2025 total revenue of $192.6M and full-year 2025 revenue of $616.3M, driven by BRIUMVI U.S. net revenue of $182.7M (Q4) and $594.1M (FY). The company raised 2026 total global revenue guidance to $875–$900M and expects BRIUMVI U.S. revenue of $825–$850M.
Other highlights: completed a $100M repurchase and authorized an additional $100M, presented multi‑year BRIUMVI data, advanced pivotal trials including a subcutaneous program, and ended 2025 with $199.5M cash and investments.
TG Therapeutics (NASDAQ: TGTX) will host a conference call on Thursday, February 26, 2026 at 8:30 AM ET to discuss fourth-quarter and full-year 2025 results and provide a 2026 business outlook.
Michael S. Weiss, Chairman and CEO, will host. A live webcast and a 30-day replay will be available on the company's Investors & Media Events page. Financial results will be issued in a press release prior to the call.
TG Therapeutics (NASDAQ: TGTX) published five-year ULTIMATE I/II open-label extension data in JAMA Neurology showing durable efficacy and consistent safety for BRIUMVI (ublituximab) in relapsing MS.
Key highlights: 3,600+ participant-years exposure, Year‑5 ARR 0.020, >70% on treatment at Year 5, 8% 24‑week CDP with continuous treatment, and no new safety signals.
TG Therapeutics (NASDAQ: TGTX) announced a collaboration with actress Christina Applegate to raise national awareness of multiple sclerosis (MS) and foster honest conversations. The initiative launched during Super Bowl LX and introduced www.NextInMS.com, a platform with Christina’s personal perspectives and expert educational content to support people living with MS.
The campaign aims to elevate patient voices, provide resources on long-term decision-making and healthcare navigation, and encourage open dialogue among patients, caregivers, and clinicians.
TG Therapeutics (NASDAQ: TGTX) announced that multiple presentations on BRIUMVI (ublituximab) will be presented at the ACTRIMS annual forum in San Diego on Feb 6, 2026. Presentations include ENABLE real‑world infusion data and pediatric ULTIMATE KIDS I and II study designs.
Posters and ePosters are available on the company publications page and the ACTRIMS ePoster gallery.
TG Therapeutics (NASDAQ: TGTX) announced its schedule of BRIUMVI® (ublituximab-xiiy) data presentations at the ACTRIMS Annual Forum, Feb 5–7, 2026 in San Diego.
Multiple poster presentations cover real-world Phase 4 ENABLE infusion experience, pediatric dose-confirmation (ULTIMATE KIDS I) and Phase 3 comparative design versus fingolimod (ULTIMATE KIDS II), plus biomarker results from ENHANCE. Abstracts are available on the ACTRIMS website and detailed posters will be posted to the company Publications page after the meeting.
TG Therapeutics (NASDAQ: TGTX) reported preliminary unaudited results and 2026 guidance on Jan 13, 2026. Full year 2025 total global revenue is approximately $616 million, with BRIUMVI U.S. net product revenue of about $182 million in Q4 and $594 million for full year 2025. For 2026 the company targets $875–900 million in total global revenue, including $825–850 million of BRIUMVI U.S. net product revenue.
2026 operating expense target is ~$350 million (ex non-cash comp) plus ~$100 million for subcutaneous BRIUMVI inventory build and secondary manufacturer start-up. Key development milestones include pivotal topline ENHANCE mid‑2026, Phase 1 azer‑cel data H2 2026, and pivotal subcutaneous BRIUMVI data year‑end 2026/1Q 2027.
TG Therapeutics (NASDAQ: TGTX) announced that Michael S. Weiss, Chairman and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 13, 2026 at 1:30 PM PST. A live webcast will be available on the company’s Events page in the Investors & Media section at http://ir.tgtherapeutics.com/events, and a replay will be posted on TG’s website after the event.
TG Therapeutics (NASDAQ: TGTX) announced that Chairman and CEO Michael S. Weiss will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference, taking place December 2–4, 2025.
The fireside chat is scheduled for Tuesday, December 2, 2025 at 12:30 PM ET. A live webcast will be available on the company’s Investors & Media Events page at http://ir.tgtherapeutics.com/events.
TG Therapeutics (NASDAQ: TGTX) said it ranked #27 on the 2025 Deloitte Technology Fast 500, a list of North America’s 500 fastest-growing tech and life sciences companies.
The company attributed its growth from fiscal years 2021–2024 to BRIUMVI revenues after BRIUMVI received FDA approval in December 2022 to treat adults with relapsing forms of multiple sclerosis. Management credited employee execution, continued product adoption, and patient/provider trust for the result.